-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the World Heart Federation estimates that worldwide more than 25-year-old adults, one in three people will suffer from a heart blood vessel disease, more than 1720 people a year die of cardiovascular disease
.
Correspondingly, in recent years, the incidence and mortality of cardiovascular diseases in China have continued to rise, and anxiety and depression are common complications in patients with cardiovascular diseases
According to the World Heart Federation estimates that worldwide more than 25-year-old adults, one in three people will suffer from a heart blood vessel disease, more than 1720 people a year die of cardiovascular disease
What is less known is that these mental illnesses may be complications of cardiovascular disease
.
According to reports, the incidence of anxiety and depression in patients with coronary heart disease is extremely high, about 18% to 60%
What is less known is that these mental illnesses may be complications of cardiovascular disease
Unfortunately, usually cardiologists often fail to identify the patient's depression and anxiety state, and thus cannot effectively control the patient's condition
.
Approximately 60% to 70% of patients with depression are treated in specialists or general outpatient clinics of various internal medicine departments with various physical symptoms as the main complaint, while the physician's ability to recognize the nature of psychological disorders is only about 15%
Approximately 60% to 70% of patients with depression are treated in specialists or general outpatient clinics of various internal medicine departments with various physical symptoms as the main complaint, while the physician's ability to recognize the nature of psychological disorders is only about 15%
JAMA
This randomized clinical trial was conducted in a tertiary nursing teaching hospital in the United States from January 2016 to May 2020 and included 128 outpatients with stable coronary heart disease and diagnosed with anxiety or HADS-A ≥ 8.
They are over 40 years old, are often sedentary, and currently do not receive mental health treatment
.
The intervention measures were 12 weeks of aerobic exercise, 3 times a week, with a heart rate reserve of 70% to 85%, escitalopram (up to 20 mg per day), or a placebo-equivalent drug
.
The study included 128 participants
The results showed that participants in the exercise group and escitalopram group reported a more significant reduction in HADS-A (exercise=- 4.
0; 95% CI, -4.
7~-3.
2; Escitalopram = -5.
7; 95% CI, -6.
4~-5.
0)
.
Compared with people who received escitalopram randomly, those who received escitalopram reported less anxiety symptoms (-1.
Compared with people randomized to receive placebo (-3.
HADS-A scores during the follow-up period of the three groups of participants
At the same time, it was found that there were significant differences in urine catecholamines (the level of anxiety-related hormones) 24 hours after the intervention (exercise z-score = 0.
05; escitalopram z-score = -0.
24; placebo z-score = 0.
36)
.
Compared with the placebo group, the exercise group and the escitalopram group had a greater decline (F1,127 = 4.
Meanwhile, the differences between the groups was found 24 hours after the intervention urine catecholamines (prompt anxiety-related hormone) significantly (score = 0.
05 z motion; escitalopram z score = -0.
24; Placebo z score = 0.
36) while , It was found that there were significant differences in urine catecholamines (an anxiety-related hormone level) 24 hours after the intervention (exercise z score = 0.
05; escitalopram z score = -0.
24; placebo z score = 0.
36)
It can be seen that escitalopram is safe and effective in reducing anxiety in patients with coronary heart disease in treating anxiety
.
.
It can be seen that escitalopram is safe and effective in reducing anxiety in patients with coronary heart disease in treating anxiety
.
references:
Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial.
JAMA Psychiatry.
Published online August 18, 2021.
doi :10.
1001/jamapsychiatry.
2021.
2236
Leave a message here
